Dear EditorWe read the article “Baseline Prolonged PR Interval and Outcome of Cardiac
Resynchronization Therapy: A Systematic Review and Meta-analysis” by Rattanawong et
al.[1] with great interest. The
authors investigated the effect of prolonged PR interval on composite outcome among
patients who received cardio resynchronized therapy. The authors conclude that prolonged
PR is associated with worse outcome in this population.I would like to commend the authors for performing a systematic review and meta-analysis
on this topic. The effect of prolonged PR interval was well-known in the general
population. However, in this specific population, the answer is unclear and was in
needed for answers, given almost half of the patients with cardiac resynchronization
therapy (CRT) had 1st degree AV block.[2] Although several previous studies reported a negative impact on
the cardiovascular outcome, they were retrospective cohort and was limited by a
relatively small number of participants. Nevertheless, the authors demonstrated a good
systematic review and performed the random-effect model with statistical perfection.However, as the authors mentioned in the article, this meta-analysis has a limitation
regarding the number of the included studies. Also, there is a difference in the
cut-point for prolonged PR interval among the included studies. Although the study by
Friedman et al. was the only study that used the cut-point of 230 ms instead of 200 ms,
they have the most included participants and has the most weight percentage in all three
forest plots. We thought that this is a crucial point as a change in risk ratio of the
study by Freidman et al.[3] could
potentially change the overall pooled RR of the meta-analysis.There are two additional studies that we thought could be included in the meta-analysis
that could affect the outcome of this meta-analysis. Studies by Stockburger et
al.[4] and Lin et al.[5] evaluated the effect of PR interval in
patients with CRT.Stockburger et al.[4] performed a post hoc
analysis from the Multicenter automatic defibrillator implantation trial with cardiac
resynchronization therapy (MADIT-CRT) trial. The authors found that patients with CRT
who had short PR interval (< 230 ms) generally had worse outcome regarding heart
failure and all-cause mortality, regardless of the QRS duration, although the authors
did not directly compare the prolonged PR interval to normal PR interval.Another study by Lin et al.[5] was based
on the secondary analysis of The Comparison of Medical Therapy, Pacing, and
Defibrillation in Heart Failure (COMPANION) trial. The authors reported that the outcome
of all-cause mortality was reduced in both normal and prolonged PR interval group when
compared to medical therapy alone, but more so in the prolonged PR interval group.
Moreover, in a multivariable Cox model, progressively longer baseline PR interval, as a
continuous variable, was associated with an increasingly greater reduction in the
primary outcome.Given that results from these two studies reported a positive correlation between PR
interval and cardiovascular outcome, including the data from the two studies could
potentially change the outcome of this meta-analysis.We appreciate the author’s comments on our original article “Baseline Prolonged PR
Interval and Outcome of Cardiac Resynchronization Therapy: A Systematic Review and
Meta-analysis”.[1] We agree
with the authors that the effect of PR interval in cardiac resynchronization therapy
(CRT) population is unknown, and therefore we conducted a systematic review and
meta-analysis on this topic.We agree that the study by Friedman et al.[2] has the most included participants and has the most
percentage in all three forest plots. However, to evaluate the effect of Friedman et
al.,[2] we performed a
sensitivity analysis by excluding one study at a time which is shown in
Supplementary Document 2 in the original article.[1] After excluding Friedman et al.,[2] there was no significant change of the risk ratio of
composite outcome (risk ratio = 1.19, 95% confidence interval: 1.04-1.36), all-cause
mortality (risk ratio=1.53, 95% confidence interval: 1.23-1.91), and heart failure
hospitalization (risk ratio = 1.6, 95% confidence interval: 1.06-2.42).[1] The meta-analysis pooled result
still has a statistically significant risk ratio even if we exclude the study by
Friedman et al.[2] Therefore, a
prolonged PR interval still predicts the outcomes of CRT regardless of the results
of the study by Friedman et al.[2]We appreciate the author’s recommendation to include the study by Stockburger et
al.[3] and Lin et
al.[4] Both studies were
included from our comprehensive search and both full-text articles were reviewed.
However, both studies were excluded from our systematic review and meta-analysis for
the following reasons.The study by Lin et al.[4] was
excluded from our systematic review and meta-analysis due to an inappropriate
comparison as demonstrated in Figure 1 of our original article.[1] Their objective is to compare the
outcomes between CRT and optimal pharmacologic therapy stratified by PR interval.
Our meta-analysis compared the outcome of prolonged PR interval versus normal PR
interval only in CRT patients.Similarly, the study by Stockburger et al.[3] was also excluded from our systematic review and
meta-analysis due to an inappropriate comparator. Stockburger et al.[3] reported that patients with
prolonged PR interval derived clinical benefit with reduction in heart failure or
death from CRT when compared to an implantable cardioverter defibrillator.[3] Therefore, their comparison was
different from our study, which was prolonged PR interval versus normal PR interval
in CRT patients.Our systematic review and meta-analysis used comprehensive search methodology and
strict inclusion and exclusion criteria; therefore our results are robust. We showed
that a prolonged PR interval in CRT patients is significantly associated with an
increased risk for all-cause mortality, composite outcome, and HF hospitalization
when compared to normal PR interval in CRT patients.[1]
Authors: Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: Daniel J Friedman; Haikun Bao; Erica S Spatz; Jeptha P Curtis; James P Daubert; Sana M Al-Khatib Journal: Circulation Date: 2016-10-19 Impact factor: 29.690
Authors: Martin Stockburger; Arthur J Moss; Helmut U Klein; Wojciech Zareba; Ilan Goldenberg; Yitschak Biton; Scott McNitt; Valentina Kutyifa Journal: Clin Res Cardiol Date: 2016-06-18 Impact factor: 5.460